Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535515 | 1.00 | CACNA1B (0.32) | CACNA1BAAK1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL3106246 | 0.90 | NNMT (0.30) | NNMT | |
| SCHEMBL3106240 | 0.90 | NNMT (0.30) | NNMT | |
| SCHEMBL2544380 | 0.83 | KCNH2 (0.38) | AAK1CYP3A4SCN9AIDO1 | |
| SCHEMBL2544379 | 0.83 | KCNH2 (0.38) | AAK1CYP3A4SCN9AIDO1 | |
| SCHEMBL2544376 | 0.83 | KCNH2 (0.38) | AAK1CYP3A4SCN9AIDO1 | |
| SCHEMBL2541819 | 0.81 | SCN9A (0.32) | SCN9A | |
| SCHEMBL2541821 | 0.81 | SCN9A (0.32) | SCN9A | |
| SCHEMBL3828466 | 0.79 | SCN9A (0.30) | SCN9A | |
| SCHEMBL3828461 | 0.79 | SCN9A (0.30) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8044044-B2 | 4-(1-amino-ethyl)-cyclohexylamine derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2094267-A2 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008078305-A2 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029623-A1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | AHR, KRAS, CNKSR1 | CACNA1B 493/4885AAK1 4061/4885MTNR1A 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.